Protalix Biotherapeutics Inc. (PLX)

0.42
0.01 2.21
AMEX : Health Services
Prev Close 0.43
Open 0.42
Day Low/High 0.42 / 0.44
52 Wk Low/High 0.42 / 1.02
Volume 159.18K
Avg Volume 757.20K
Exchange AMEX
Shares Outstanding 145.57M
Market Cap 62.83M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Protalix BioTherapeutics' Pegunigalsidase Alfa Receives Fast Track Designation From The U.S. Food And Drug Administration

Protalix BioTherapeutics' Pegunigalsidase Alfa Receives Fast Track Designation From The U.S. Food And Drug Administration

Fast Track designation highlights high unmet medical need in the treatment of Fabry disease

Protalix BioTherapeutics To Participate In The 14th Annual WORLDSymposium™ 2018

Protalix BioTherapeutics To Participate In The 14th Annual WORLDSymposium™ 2018

Data to be presented in an oral presentation and two poster presentations

IIROC Trading Halt - PLX

IIROC Trading Halt - PLX

Protalix BioTherapeutics Announces Presentation To Be Made At The New Horizons In Fabry Disease Conference

Protalix BioTherapeutics Announces Presentation To Be Made At The New Horizons In Fabry Disease Conference

Oral Presentation of Long Term Results from the Phase I/II Open-Label Extension Trial of PRX-102 for Fabry Disease

Protalix BioTherapeutics Completes Private Note Exchange Of $9 Million Notes Maturing September 2018 For $8.55 Million Notes Maturing February 2022

Protalix BioTherapeutics Completes Private Note Exchange Of $9 Million Notes Maturing September 2018 For $8.55 Million Notes Maturing February 2022

Concurrently the Company Completes Private Placement of $10 Million Convertible Notes

Protalix BioTherapeutics Announces FDA Approval To Operate Its Current Facility as A Multi-Product Facility

Multi-product facility to support the potential manufacturing of both pegunigalsidase alfa and taliglucerase alfa on a commercial scale

TheStreet Quant Rating: D (Sell)